Amsterdam, NL, 6 September 2007 – Elsevier announced today that it is launching a new journal, Stem Cell Research, in September 2007. The journal will be published 6 times a year and will focus on high quality research in all aspects of stem cell science and applications.
The new journal (www.elsevier.com/locate/scr) will cover all aspects of stem cell research, including embryonic stem cells, tissue-specific stem cells, cancer stem cells, developmental studies, stem cell genomics and translational research. Original research, short reports and invited reviews will be available to more than 10 million researchers via Elsevier’s publication platform ScienceDirect.
Stem cells, which can differentiate into any type of body tissue, are seen as key tools in scientist’s understanding of basic cell functioning and are used to study development, cancer and organ function. Because of their ability to divide and develop into any kind of cell, they may have therapeutic potential in injury and disease.
Professor Andrew Elefanty, at the Monash Immunology and Stem Cell Laboratories in Melbourne Australia, will serve as Editor-in-Chief with Associate Editors Christine Mummery (University of Utrecht Medical Center) Markus Grompe (Oregon Stem Cell Center), and Paul J. Simmons (University of Texas-Houston Center for Stem Cell Research). Twenty internationally-recognized experts have agreed to serve on the Editorial Board.
"In a few short years, stem cell research, with the promise of new cell-based therapies for debilitating diseases, has captured the imagination of scientists and raised the hopes of the general public like no other scientific endeavour, “says Editor-in-Chief Andrew Elefanty. “To disseminate the results of this continuing, exponential increase in research into stem cells, we are proud to announce the timely launch of Stem Cell Research, dedicated to the publication of high-quality peer-reviewed studies spanning the breadth of embryonic and adult stem cell science. "
“It’s a field growing faster than any other in the life sciences,” says Publisher Noelle Gracy. “It was a natural choice for a new journal launch, and we’re very fortunate to be supported by the top researchers in the field. Our articles in press are already receiving citations—it’s clearly a fast-moving area.”
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Journal
Stem Cell Research